<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04981899</url>
  </required_header>
  <id_info>
    <org_study_id>r/r cHL NICE-40</org_study_id>
    <nct_id>NCT04981899</nct_id>
  </id_info>
  <brief_title>A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma</brief_title>
  <acronym>NICE-40</acronym>
  <official_title>Multicenter Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Petersburg State Pavlov Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Petersburg State Pavlov Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nivolumab is an anti-PD-1 antibody highly effective in patients with relapsed/refractory&#xD;
      classical Hodgkin lymphoma. A PET-adapted regimen of Nivo combined with ICE as first salvage&#xD;
      therapy was shown to induce high response rates and favorable progression-free survival as a&#xD;
      bridge to autologous stem cell transplantation, allowing to omit salvage chemotherapy in a&#xD;
      substantial proportion of r\r cHL patients. This study evaluates the safety and efficacy of&#xD;
      PET-adapted treatment of nivolumab at the fixed dose of 40 mg in combination with ifosfamide,&#xD;
      carboplatin, and etoposide (NICE-40) in patients with relapsed/refractory Hodgkin Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of grade 3 or higher treatment-related adverse events by CTCAE 4.03</measure>
    <time_frame>12 months</time_frame>
    <description>Toxicity parameters based on NCI CTCAE 4.03 grades: hematological toxicity (CBC), hepatotoxicity (liver function tests), nephrotoxicity (creatinine), neurotoxicity (attending physician assessment), fatigue (attending physician assessment), rash (attending physician assessment), colitis (attending physician assessment), pneumonitis (attending physician assessment), autoimmune disorders (level of hormones, presence of autoimmune antibodies, attending physician assessment).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>12 months</time_frame>
    <description>Overall response rate (ORR), defined as the proportion of patients with complete response (CR) or partial response (PR) in measurable lesions as defined by LYRIC and Lugano 2014 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Main arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive 6 cycles of nivolumab at the fixed dose of 40 mg, with subsequent assessment of response by PET-CT. Patients with CR will proceed to ASCT.&#xD;
Patients with &lt;CR after nivolumab monotherapy will be treated with 2 cycles of a combination of nivolumab at the fixed dose 40 mg, ifosfamide, carboplatin and etoposide (NICE-40), with subsequent PET-CT assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>6 infusions of nivolumab at a fixed dose of 40 mg, 14 days apart, and infusion of nivolumab on day 0 of the NICE-40.</description>
    <arm_group_label>Main arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ifosfamide</intervention_name>
    <description>5000 mg / m2, 24-hour infusion on day 2 of the NICE-40.</description>
    <arm_group_label>Main arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Optimized to get AUC = 5 (max. 800 mg) on day 2 of the NICE-40.</description>
    <arm_group_label>Main arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>100 mg / m2 intravenously on 1-3 days of the NICE-40.</description>
    <arm_group_label>Main arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis: Histologically confirmed Hodgkins lymphoma&#xD;
&#xD;
          -  Relapsed or refractory disease after the first line of treatment&#xD;
&#xD;
          -  Age 18-70 years old&#xD;
&#xD;
          -  Ejection fraction greater than 50%&#xD;
&#xD;
          -  ECOG 0-2 status&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  No severe concurrent illness&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled bacterial or fungal infection at the time of enrollment&#xD;
&#xD;
          -  Requirement for vasopressor support at the time of enrollment&#xD;
&#xD;
          -  Severe organ failure: creatinine more than 2 norms; ALT, AST more than 5 norms;&#xD;
             bilirubin more than 1.5 norms&#xD;
&#xD;
          -  Karnofsky index &lt;30%&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Somatic or psychiatric disorder making the patient unable to sign an informed consent&#xD;
&#xD;
          -  Active or prior documented autoimmune disease requiring systemic treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Kulagin, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>RM Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation, Pavlov University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kirill Lepik, MD,PhD</last_name>
    <phone>+78123386265</phone>
    <email>lepikkv@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalia Mikhailova, MD,PhD</last_name>
    <email>bmt.lymphoma@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Medicine Research Center of oncology named after N.N. Petrov</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Pesochny</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey Shalaev</last_name>
      <phone>+79215590113</phone>
      <email>Shalaev.haemonc@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Irkutsk Regional Cancer Center</name>
      <address>
        <city>Irkutsk</city>
        <zip>664044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Demchenkova</last_name>
      <phone>+79148720236</phone>
      <email>mdemchenkova@yandex.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Petersburg State Pavlov Medical University</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>July 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Petersburg State Pavlov Medical University</investigator_affiliation>
    <investigator_full_name>Ivan S Moiseev</investigator_full_name>
    <investigator_title>Vice-director for science RM Gorbacheva Institute</investigator_title>
  </responsible_party>
  <keyword>Hodgkin Lymphoma, Nivolumab, Ifosfamide, Carboplatin, Etoposide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

